Stock price movement
On April 5, Sangamo Therapeutics (SGMO) closed at $12.58, 3.62% above its previous closing price, 100.96% above its 52-week low of $6.26, and 38.78% below its 52-week high of $20.55. The company’s market capitalization was $1.29 billion, and its price-to-sales and price-to-book ratios were 15.23x and 3.51x, respectively.
Between February 28 (Sangamo’s fourth-quarter earnings release) and April 5, its stock rose 39.62% from $9.01 to $12.58. In the fourth quarter, the company’s revenue rose 105.22% YoY (year-over-year) to $26.84 million, beating analysts’ estimate by $4.33 million. Its non-GAAP EPS fell 20% YoY to -$0.18 but beat analysts’ estimate by $0.04.
On April 5, Amarin (AMRN) closed at $19.75, 0.71% above its previous closing price, 740.43% above its 52-week low of $2.35, and 15.36% below its 52-week high of $23.33. The company’s market capitalization was $6.46 billion, and its price-to-sales and price-to-book ratios were 28.18x and 47.0x, respectively.
Between February 27 (Amarin’s fourth-quarter earnings release) and April 4, its stock fell 6.75% from $21.18 to $19.61. To learn more, read What Wall Street Recommends for Amarin after Q4 2018 Results.
Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.
Analysts’ recommendations and target prices
Analysts’ average target price of $21 implies a 66.93% upside for Sangamo stock based on its April 5 closing price. They reduced their target price for the stock from $22.71 in January and February to $19 in March before raising it again. Of the eight analysts covering Sangamo, three recommend “strong buy,” two recommend “buy,” and three recommend “hold.” Their highest and lowest target prices are $34 and $10, respectively.
Meanwhile, analysts’ average target price of $32.60 for Amarin stock implies a 65.06% upside based on its April 5 closing price. They reduced their target price for the stock from $34.80 in January to $34 in February and March, and have reduced it again. Of the five analysts covering Amarin, three recommend “strong buy,” and two recommend “buy.”